In children, when is parenteral iron indicated, what are the recommended dosing regimens, monitoring parameters, safety precautions, and contraindications, and which iron formulations are preferred?

Parenteral Iron Therapy in Children: Precautions and Clinical Guidelines

Iron sucrose is the preferred parenteral iron formulation for children, with the best safety profile and most extensive pediatric data, and should be reserved for children who cannot tolerate or fail oral iron therapy, with strict attention to maximum dose limits and monitoring for hypersensitivity reactions. 1

Indications for Parenteral Iron

Primary indication: Parenteral iron should be used only when enteral (oral) iron supplementation is not tolerated or fails to maintain adequate iron status. 1

Specific Clinical Scenarios:

• Long-term parenteral nutrition (>3 weeks) when enteral iron cannot maintain adequate iron status 1
• Chronic kidney disease in children on dialysis or erythropoietin therapy 1, 2
• Severe iron deficiency anemia unresponsive to oral therapy after 4 weeks of adequate dosing 3, 4
• Gastrointestinal conditions (inflammatory bowel disease, celiac disease, intestinal failure) where oral absorption is impaired 5, 6
• Intolerance to oral iron with significant gastrointestinal side effects preventing compliance 3, 5

Critical caveat: Do NOT use parenteral iron routinely for short-term parenteral nutrition (<3 weeks). 1

Preferred Iron Formulations and Safety Profile

First-Line Choice: Iron Sucrose

Iron sucrose has the strongest safety and efficacy data in children and is the recommended formulation for intermittent infusions. 1

• FDA approval: Ages ≥2 years for chronic kidney disease in the USA 1, 2
• Safety data: 232 children received 1624 doses with very few serious adverse reactions; no anaphylactic reactions in randomized trials 1
• Advantage: Significantly fewer adverse effects compared to iron dextran 1

Alternative Formulations (in order of preference):

• Iron gluconate: FDA-approved from age ≥6 years; limited pediatric data (216 doses in 23 children) with only minor adverse events (pain, transient hypotension) 1
• Iron carboxymaltose: Very limited pediatric data (147 doses in 72 children) with only 3 mild adverse reactions 1
• Iron dextran: Higher risk of allergic reactions; requires mandatory test dose before treatment 1

Important regulatory note: No intravenous iron product is currently approved for pediatric use in Europe, though these products are nevertheless used off-label. 1

Dosing Regimens

For Parenteral Nutrition (Daily Administration):

• Preterm infants: 200-250 μg/kg/day 1
• Infants and children: 50-100 μg/kg/day, maximum 5 mg/day 1, 7

For Intermittent Infusions (Iron Sucrose):

Hemodialysis-dependent children (≥2 years):

• Maintenance dose: 0.5 mg/kg (maximum 100 mg per dose) every 2 weeks for 12 weeks 2
• Administration: Undiluted slow IV injection over 5 minutes OR diluted in 0.9% NaCl (1-2 mg/mL concentration) over 5-60 minutes 2

Non-dialysis or peritoneal dialysis children (≥2 years) on erythropoietin:

• Maintenance dose: 0.5 mg/kg (maximum 100 mg per dose) every 4 weeks for 12 weeks 2

General pediatric use (off-label):

• Individual doses typically range from 100-200 mg 4
• Total treatment courses range from 200-1200 mg depending on severity 4
• Infusions given on alternate days up to 3 times per week 4

Critical Safety Precautions

Hypersensitivity Reactions

Personnel trained in emergency treatment must be immediately available, with epinephrine, diphenhydramine, and corticosteroids on hand. 7, 2

Symptoms to monitor:

• Dyspnea, wheezing, hypotension 1
• Nausea, vomiting, abdominal pain 1
• Arthralgia, myalgia, skin rash 1

Test dosing for iron dextran:

• <10 kg: 10 mg test dose 7
• 10-20 kg: 15 mg test dose 7

• 20 kg: 25 mg test dose 7

Dose-Related Toxicity

Never exceed the maximum recommended dose of 300 mg iron sucrose per infusion in children. 1

Critical warning: Systemic iron toxicity with hepatocellular damage has been reported in a pediatric patient receiving 16 mg/kg of iron sucrose—far exceeding recommended dosing. 1, 7

Administration Precautions

• Do not dilute iron sucrose to concentrations below 1 mg/mL 2
• Administer early during dialysis session (within first hour) for hemodialysis patients 2
• Monitor for hypotension during and immediately after infusion 1, 2

Monitoring Parameters

Regular monitoring of iron status is mandatory to prevent both iron deficiency and iron overload. 1

Required Laboratory Tests:

• Hemoglobin: Check at baseline and after 4 weeks of treatment 8, 7
• Ferritin: Monitor regularly in long-term therapy 1, 7
• Additional studies if non-responsive: MCV, RDW, transferrin saturation 8, 7

Expected Response:

• Hemoglobin should increase ≥1 g/dL after 4 weeks of adequate therapy 8, 7
• Normalization of ferritin and transferrin saturation confirms adequate response 7
• Hemoglobin typically normalizes within 31-42 days after first infusion 4

Contraindications

Absolute contraindications:

• Known hypersensitivity to iron sucrose or any component 2
• Evidence of iron overload 2
• Anemia not caused by iron deficiency 2

Relative contraindications:

• Active infection (iron may promote bacterial growth) 1
• Collagen vascular diseases (increased risk of adverse effects with iron dextran) 1

Common Pitfalls and How to Avoid Them

Pitfall #1: Using parenteral iron as first-line therapy

• Solution: Always attempt oral iron first (3-6 mg/kg/day elemental iron) for 4 weeks before considering parenteral therapy 8, 9

Pitfall #2: Exceeding maximum single doses

• Solution: Never give >300 mg iron sucrose per infusion; the only significant adverse reaction in pediatric series occurred when this limit was exceeded 1

Pitfall #3: Inadequate emergency preparedness

• Solution: Ensure resuscitation equipment and medications (epinephrine, diphenhydramine, corticosteroids) are immediately available before every infusion 7, 2

Pitfall #4: Failing to monitor for iron overload

• Solution: Check ferritin regularly in children on long-term parenteral nutrition or repeated courses of IV iron 1, 7

Pitfall #5: Using iron dextran without test dosing

• Solution: Always administer appropriate weight-based test dose before therapeutic dose of iron dextran 1, 7